Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Short-Course Chemoradiotherapy for Resectable Gastric Adenocarcinoma
NCT04523818Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capecitabine and fluorouracil in gastric adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Started Aug 2020; status: active, not recruiting.
02
Drugs
capecitabinefluorouracil
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04523818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523818.